Pinealon Guide

Pinealon (Glu-Asp-Arg / EDR) is a synthetic tripeptide from the Khavinson bioregulator family, derived from pineal gland tissue. Unlike Epithalon which focuses on telomere biology, Pinealon specializes in neuroprotection — reducing oxidative damage in neural tissue, protecting retinal cells from degeneration, and supporting circadian rhythm regulation through pineal gland support.

Pinealon is a tripeptide containing the amino acid sequence Glutamic acid-Aspartic acid-Arginine (Glu-Asp-Arg, abbreviated EDR). It belongs to the Khavinson short peptide bioregulator system — a family of tissue-specific peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology by Dr. Vladimir Khavinson. Each Khavinson peptide is isolated from or inspired by a specific tissue (brain, thymus, liver, pineal gland) and is thought to provide tissue-specific regulatory signals.

Pinealon's primary research focus has been neuroprotection and retinal health. Studies by Khavinson's group and collaborators have shown Pinealon reduces oxidative stress markers in neural tissue, protects retinal ganglion cells from apoptosis in glaucoma models, and supports melatonin regulation in the aging pineal gland. It penetrates the blood-brain barrier effectively, giving it direct access to the CNS.

Pinealon is not FDA-approved and is used as a research peptide. It is commonly paired with Epithalon in longevity protocols — the two peptides are complementary, with Epithalon targeting telomere biology and systemic anti-aging while Pinealon specifically addresses neural and retinal tissue protection. Both are used on Khavinson's classic 10-day cycle protocol twice yearly.

Evening or bedtime injection is preferred to align with pineal gland circadian activity. Store at 2–8°C after reconstitution. Use Shotlee to log 10-day cycles and track sleep quality, vision clarity, and energy over time.